KPTI vs. CNTX, OPTN, AMLX, PDSB, RNAC, NVCT, VTGN, DMAC, MCRB, and COYA
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Context Therapeutics (CNTX), OptiNose (OPTN), Amylyx Pharmaceuticals (AMLX), PDS Biotechnology (PDSB), Cartesian Therapeutics (RNAC), Nuvectis Pharma (NVCT), Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Seres Therapeutics (MCRB), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry.
Context Therapeutics (NASDAQ:CNTX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Context Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Context Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 255.03%. Karyopharm Therapeutics has a consensus price target of $4.80, indicating a potential upside of 324.78%. Given Context Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Context Therapeutics.
14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 9.4% of Context Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Karyopharm Therapeutics received 512 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave Karyopharm Therapeutics an outperform vote while only 66.67% of users gave Context Therapeutics an outperform vote.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -104.18%. Context Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
In the previous week, Karyopharm Therapeutics had 7 more articles in the media than Context Therapeutics. MarketBeat recorded 18 mentions for Karyopharm Therapeutics and 11 mentions for Context Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.96 beat Context Therapeutics' score of 0.21 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.
Summary
Karyopharm Therapeutics beats Context Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
